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PP.3.117 TREATMENT-INDUCED CHANGES IN CLINIC VS. HOME
VS. AMBULATORY BLOOD PRESSURE AND CHANGES
IN TARGET ORGAN DAMAGE: AN INTERIM ANALYSIS
G. Stergiou1, N. Karpettas1, A. Protogerou1, E. Nasothimiou1, I. Moyssakis2.
1Hypertension Center, Third University Department of Medicine, Sotiria Hospital,
Athens, Greece, 2Department of Cardiology Laikon Hospital, Athens, Greece
Objective: To assess the relationship of treatment-induced changes in clinic
(CBP), home (HBP) and ambulatory blood pressure (ABP) with the changes
in target organ damage.
Methods: In the context of an ongoing prospective study, 39 untreated
subjects with elevated blood pressure (BP) (mean age, 50.2 10.1 years,
21 men) had CBP (3 visits, oscillometric device Microlife WatchBP Office),
HBP (7 days, oscillometric device Microlife WatchBP Home) and ABP
measurements (24-hours, oscillometric devices SpaceLabs 90207/90217 or
Microlife WatchBP O3). Target organ damage was assessed by echocardio-
graphic left-ventricular mass index (LVMI), microalbuminuria (MAU) (two
first-morning spots) and carotid-femoral pulse-wave velocity (PWV; Com-
plior) at baseline (untreated) and after 12 months of antihypertensive
drug treatment.
Results: The correlation coefficients of the treatment-induced changes
in MAU (A¨MAU: baseline vs. after 12 months of treatment) with the
respective treatment-induced BP changes (A¨BP) were superior for ABP
(systolic/diastolic, 24 h r¼ 0.30/0.32, p¼ 0.08/0.06; awake r¼ 0.29/0.26,
p¼ 0.09/0.13; asleep r¼ 0.27/0.37, p¼ 0.13/0.03) than for HBP or CBP
(all p¼NS). On the other hand, A¨PWV was more closely associated with
A¨HBP (r¼ 0.34/0.28 p¼ 0.07/0.14) or A¨CBP (r¼ 0.21/0.31, p¼ 0.26/0.10)
than with A¨ABP (all p¼NS). Finally, A¨LVMI was correlated with A¨HBP
(r¼ 0.32/0.33, p¼ 0.06/0.05), A¨CBP (r¼ 0.51/0.25, p¼ 0.002/0.15), and
awake A¨ABP (r¼ 0.22/0.40, p¼ 0.20/0.02), but not with 24-hour or night-
time A¨ABP.
Conclusion: Treatment-induced changes in different indices of target organ
damage are not equally predicted by the BP change assessed by different
measurement methods. These data suggest that CBP, HBP and ABP
measurements are complementary rather than competitive methods in
the assessment of the effects of antihypertensive treatment on target organ
damage.
PP.3.118 CLINICAL IMPLICATIONS FOR TREATMENT
DECISIONS OF REPLACING THE MERCURY
SPHYGMOMANOMETER WITH A
PROFESSIONAL OSCILLOMETRIC DEVICE IN A
HYPERTENSION CLINIC
G. Stergiou, P. Lourida, D. Tzamouranis. Hypertension Center, Third University
Dept of Medicine, Sotiria Hospital, Athens, Greece
Objective: Oscillometric devices are being widely used for ambulatory,
home and office blood pressure (BP) measurement and several of them have
been validated using established protocols. This cross-sectional study
assessed the impact on antihypertensive treatment decisions of replacing
the mercury sphygmomanometer by a validated professional oscillometric
device in a hypertension clinic.
Methods: Consecutive subjects attending an Outpatient Hypertension
Clinic had simultaneous same arm BP measurements (Y connector) using
a standard mercury sphygmomanometer and a validated professional oscillo-
metric device (BpTRU). For each device the average systolic BP of triplicate
measurements 140 mmHg and/or diastolic 90 mmHg was used to define
uncontrolled hypertension.
Results: A total of 5,070 simultaneous BP measurements were obtained from
755 subjects (mean age 58.1 12.9 years) in 1,706 clinic visits within 14
months. In 285 visits (16.7%) the mercury and the oscillometric BP measure-
ments leaded to different conclusion regarding the diagnosis of uncontrolled
hypertension. In 5.3% of the visits the diagnostic disagreement was con-
sidered as ‘‘clinically important’’ (BP exceeding the diagnostic threshold
by 5 mmHg) and in 0.8% as ‘‘large’’ (BP exceeding the threshold by
10 mmHg).
Conclusion: These data suggest that the replacement of the mercury
sphygmomanometer by a validated professional oscillometric device in a
hypertension clinic will result into different treatment decisions in about 5%
of the cases. Therefore, and because of the known problems when using
mercury devices and the auscultatory technique in clinical practice, the
oscillometric devices are regarded as reliable alternatives to the mercury
sphygmomanometer for office BP measurement.
PP.3.119 REFERENCE VALUES OF CENTRAL BLOOD
PRESSURE AND PULSE WAVE VELOCITY




A. Saint-Remy, J.M. Krzesinski. University Hospital of Liege, Liege, Belgium
Aim: The present study aimed to define reference values of central blood
pressure (cBP) and Pulse Wave Velocity (PWV) together with 24H ABPM in
healthy normotensive young adults before starting a follow-up of their CV
profile modifications over time.
Method: Office BP (OBP), heart rate (HR), cBP and PWV (SphygmoCor)
and 24 h ABPM (Spacelabs 90207) were measured in 94 healthy young
caucasian (mean age: 22.5 2.8 y, range:19–30; M/W:47/47). Height, weight,
family and personal medical history, smoking and physical activity were
recorded. None were under antihypertensive medications; 86% of women
were on pill.
Results: Mean BMI was 21.6 3 Kg/m2. Twelve % were smokers, 26% and
21% had a family history of HT and Diabetes, respectively. Mean OBP in
men was 123–74 mmHg with 95th P at 139- 87 and mean cBP was 103–73
with the 95th P at 116–85, mean 24hABPM was 120–69 with a 95th P at
131–78 mmHg. In women the mean BP and 95th P were for OBP: 116–
71,132–88; for cBP: 99–72,119–88; and for 24hABPM: 113–70,127–
80.Boys, taller and heavier, had significantly higher OBP, cBP, Pulse
Pressure (PP) and Systolic ABPM than girls. Mean PWV was 5.8 0.9 m/s
with a P90th at 7 m/s. PWV was moderately related to cBP (r¼ 0.27,
P¼ 0.01). Girls had systematically higher HR than boys. cSBP was correlated
to 24 h ABP (0.44, P< 0.0001), to 24 h MAP (0.51, P< 0.0001). Interestingly,
participants with a family history of HT and/or diabetes,had a higher PWV
(P¼ 0.07) than those with no family history.
Conclusions: Observed in a healthy population, our data provide
reference values of central BP and PWV for a 20–30 y. range of age.
OBP and Daytime ABPM were very close while Central Systolic BP were
significantly lower. These data give opportunity to follow up this popu-
lation regarding the BP evolution with age and cardiovascular risk factors
appearance according to these three ways of measurement and to compare
these relations in different pathologies and treatment related to high blood
pressure.
PP.3.120 EFFECT OF DOSING TIME OF ANGIOTENSIN II
RECEPTOR BLOCKADE TITRATED BY
SELF-MEASURED BP ON CARDIORENAL
PROTECTION IN HYPERTENSIVES:
J-TOP STUDY
K. Kario, S. Hoshide, M. Shimizu, Y. Yano, K. Eguchi, J. Ishikawa, S.
Ishikawa, K. Shimada. Jichi Medical University School of Medicine, Shimotsuke,
Japan
Objectives: To study the impact of the dosing time of an angiotensin II
receptor blocker (ARB) titrated by self-measured home blood pressure
(HBP) on cardiorenal damage in hypertensives.
Methods: We conducted an open-label multicenter trial, the J-TOP
study, that enrolled 450 hypertensives with self-measured systolic
HBP>135 mmHg. The study patients were stratified into 3 groups
according to the difference between their morning and evening SBPs
(ME) difference: a morning hypertension group (ME difference>15
mmHg; n¼ 170), an ME hypertension group (0 mmHg< ME difference
<15 mmHg; n¼ 198), and an evening hypertension group (ME
difference<0 mmHg; n¼ 82). Subjects were then randomly allocated to
receive bedtime-dosing or awakening-dosing of candesartan (þdiuretic as
needed) titrated to achieve a target systolic HBP<135 mmHg. The
6-month change in the urinary albumin/creatinine ratio (UACR) was
assessed.
Results: In total patients, the UACR was more markedly reduced in the
bedtime-dosing group than in the awakening-dosing group (-45.7 vs.
-34.5%, p¼ 0.02), while there were no differences in the reduction of
any of the HBPs including the sleep BPs between the 2 groups. Among
the 3 subgroups stratified by the ME difference, the difference in the
UACR reduction between the bedtime-dosing and awakening-dosing
groups was only significant in the morning hypertension group (-50.6 vs.
-31.3%, p¼ 0.02).
Conclusion: In HBP-guided antihypertensive treatment in hypertensives,
bedtime dosing of an ARB was superior to awakening-dosing for reducing
microalbuminuria.
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